# A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

> **NCT04279405** · PHASE1 · COMPLETED · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 43 (actual)

## Conditions studied

- Small Lymphocytic Lymphoma
- Lymphoplasmacytic Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** YY-20394

## Key facts

- **NCT ID:** NCT04279405
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2021-09-30
- **Final completion:** 2023-06-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04279405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04279405, "A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04279405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*